Coherus BioSciences Inc (CHRS)

[Mile High Marauder]

21 million share short!! What is going on!

[Monksdream]

CHRS new 52 week low

[frans]

about end dec.23 finish tests 400 peoples - FDA commercialization about june 24 if no problems

[eneels01]

Wow, instead of having a chance to go to $9, this stock has more of a chance to hit $1 by 2024. Oh well, I will just keep averaging down and sell when it eventually hits $5 again. Unfortunately that might not take place until 2025 or even 2026…

[frans]

I selled and come back begin jan 24 after finish test 400 peoples about end dec. 23

[Mile High Marauder]

Any idea who has this much stock to sell? I don’t see very many 5% holders.

[frans]

what is going on here ??

[TimeFades]

Yup

[Monksdream]

For now

[TimeFades]

Looking strong

[Monksdream]

Few and far between in the biomed sector this year

[frans]

slowly up from here

[Monksdream]

CHRS morning rally

[TimeFades]

Back in

[TimeFades]

Sold out first thing at 4 watching

[TheFinalCD]

WATCH 2:22

[Mile High Marauder]

Didn’t mean dog

[Mile High Marauder]

This dog has an 18 million shares short in it, somebody’s been betting big against it or think they know something we don’t

[TIMGZ]

INSTITUTIONS ARE BUYING UP ALL AND EVERY POTENTIALS******STILL, IT WILL EVENTUALLY DRIZZLE DOWN

[TheFinalCD]

I bought the dip, but the float is practically owned by Institutions

thats the problem I see here

80% https://finviz.com/quote.ashx?t=CHRS&p=d

[TIMGZ]

CHRS****OPPORTUNITY TO BUY MORE OR STILL WAIT FOR DIRECTION??????????

[TheFinalCD]

3.10 GOING WRONG WAY

MAYBE THE NEWS ISNT AS BIG AS HOPED??

[TheFinalCD]

LOQTORZI $CHRS

What is nasopharyngeal carcinoma? Nasopharyngeal carcinoma (also known as NPC) is a rare tumor of the head and neck which originates in the nasopharynx. The nasopharynx is located at the very back of the nose near the Eustachian tubes (Figure).

good part is

LOQTORZI is the first and only FDA-approved treatment for NPC

[TimeFades]

Moon?

[Runners123]

Coherus BioSciences, Inc. (“Coherus”, NASDAQ: CHRS), and Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences, HKEX: 1877; SSE: 688180) today announced that the U.S. Food and Drug Administration (FDA) approved LOQTORZI™ (toripalimab-tpzi) in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. The approval was based on results of the JUPITER-02 Phase 3 study and the POLARIS-02 Phase 2 study and is irrespective of a patient’s PD-L1 status. LOQTORZI is a next-generation, programmed death receptor-1 (PD-1) monoclonal antibody that blocks PD-1 ligands PD-L1 and PD-L2 with high potency at a unique site on the PD-1 receptor, enabling the immune system to activate and kill the tumor.
In the JUPITER-02 Phase 3 study, LOQTORZI combined with chemotherapy significantly improved progression-free survival (PFS), reducing the risk of disease progression or death by 48% compared to chemotherapy alone. LOQTORZI also demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS), with treatment resulting in a 37% reduction in the risk of death versus chemotherapy alone.

The safety profile of LOQTORZI was consistent with the PD-1 inhibitor class. The incidence of Grade ≥3 adverse events (AEs) (89.7% vs 90.2%) and fatal AEs (3.4% vs 2.8%) was similar between the two arms. AEs leading to discontinuation of LOQTORZI versus placebo (11.6% vs 4.9%), immune-related adverse events (irAEs) (54.1% vs. 21.7%), and Grade ≥3 irAEs (9.6% vs. 1.4%) were more frequent in the LOQTORZI arm.

In the POLARIS-02 clinical study LOQTORZI demonstrated durable antitumor activity in patients with recurrent or metastatic NPC who failed previous chemotherapy, with an objective response rate (ORR) of 20.5%, a disease control rate (DCR) of 40.0%, and a median OS of 17.4 months with an acceptable safety profile.

NPC is an aggressive cancer that starts in the nasopharynx, the upper part of the throat behind the nose and near the base of skull. Due to the location of the primary tumor, surgery is rarely an option, and patients with localized disease are treated primarily with radiation and chemotherapy. LOQTORZI is the first FDA-approved agent for NPC patients.

“LOQTORZI’s first approval is a pivotal event for Coherus as an innovative oncology company. As a next generation PD-1 inhibitor it is the keystone of our I-O strategy to extend cancer patient survival as shown with the impressive results in NPC,” said Denny Lanfear, Chairman and Chief Executive Officer of Coherus. “We are particularly excited to now turn our attention to developing LOQTORZI across multiple tumor types in combination with I-O agents that target the tumor microenvironment, such as our IL27-targeted antibody, casdozokitug, and our CCR8 inhibitor CHS-114, potentially greatly expanding the number of cancer patients achieving improved survival benefit.”

“Today’s FDA approval of LOQTORZI is very encouraging for those living with NPC who currently have very limited treatment options and are in need of new therapies to treat this aggressive and life-threatening form of cancer,” said Jong Chul Park, M.D., Assistant Professor, Harvard Medical School and attending physician at the Center for Head and Neck Cancers at Massachusetts General Hospital Cancer Center. “LOQTORZI is a new treatment option that has demonstrated the ability to significantly improve PFS and OS and should quickly emerge as the new standard of care when used in combination with chemotherapy.”

The recommended LOQTORZI dose with cisplatin and gemcitabine is 240 mg every three weeks until disease progression, unacceptable toxicity, or up to 24 months. The recommended LOQTORZI dose as a single agent for previously treated NPC is 3 mg/kg every two weeks until disease progression or unacceptable toxicity.

LOQTORZI is expected to be available in the United States in Q1 2024.

“The impressive results from JUPITER-02 and POLARIS-02 have provided conclusive evidence that establishes toripalimab, in combination with chemotherapy or as monotherapy, as the standard therapy for advanced NPC,” said Professor Ruihua Xu of Sun Yat-sen University Cancer Center, the principal investigator of JUPITER-02 and POLARIS-02. “This great achievement was only made possible through the solid foundation laid by countless oncology experts over decades of in-depth research, as well as the selfless dedication of the patients and research teams involved in our toripalimab studies. We hope that this promising therapy will close the treatment gap for international NPC patients struggling to find effective therapies, bringing them renewed hope for better survival.”

“We’re excited to reach another significant company milestone of ‘going overseas’,” said Dr. Ning LI, Chief Executive Officer of Junshi Biosciences. “Following etesevimab, toripalimab has become Junshi Biosciences’ second product to receive FDA approval for commercialization—an achievement that will further enhance the company’s international presence. Currently, the establishment of toripalimab’s global commercialization network is in progress, and the network aims to span over 50 countries. In accordance with the company’s ‘In China, For Global’ strategy, we will continue working with our collaborators to promote the commercialization of toripalimab in other regions, in order to provide innovative and high-quality drugs from China to more patients overseas.”

[TheFinalCD]

3.54

[TheFinalCD]

$CHRS 3.44 NHOD

[TheFinalCD]

https://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardid=12753&searchstr=CHRS&srchyr=2023

[TheFinalCD]

https://www.globenewswire.com/news-release/2023/10/27/2768663/33333/en/Coherus-and-Junshi-Biosciences-Announce-FDA-Approval-of-LOQTORZI-toripalimab-tpzi-in-All-Lines-of-Treatment-for-Recurrent-or-Metastatic-Nasopharyngeal-Carcinoma-NPC.html

[Mile High Marauder]

Where in the world is all the selling coming from-in this stock? Somebody really must not have liked the acquisition they did? 17%+ short?!? Management better get their act together. They’ve taken a stock from $8 to $3 in six months! $20 plus price targets? Seems like some serious BS to me and I own the stock

[eneels01]

$9 possible by 2024…

[AJ Freely]

$CHRS - 👆Up 11.7% Pre-Market/ Current Price $4.94
👉Reports Q2 '23 Financial Results and Business Highlights
👉Net revenue rose 81% from prior quarter to $58.7 million – 👉CIMERLI® net sales quadrupled to $26.7 million compared to prior quarter

[SmokeSignals]

Hey...I went and bought a handful of calls after I got out of them last week. doing pretty good. might dump them today...freakin Jans...5's and 10 strikes..hope your OK...

[SmokeSignals]

hey..have a great holiday! let me know whats next. Is all good. Nobody can get em all right. We keep trying....stay safe

[SmokeSignals]

uh oh..i'm rootin for $3 (sorry) out of them calls

[SmokeSignals]

lol got calls and puts>puts looking sweet @ the moment, hope it goes the other way (north) lol

[stock1ace1]

10 mill short squeeze watch on fda news today $

[stock1ace1]

Chrs gapping @9$

[SmokeSignals]

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Coherus Biosciences with a $18.60 average price target, which is a 183.97% upside from current levels.
https://ih.advfn.com/stock-market/NASDAQ/coherus-biosciences-CHRS/stock-news/89617584/coherus-biosciences-chrs-receives-a-buy-from-mizuh

[SmokeSignals]

holdin a whole bunch of calls 5's, 7 1/2's, and 10's lol with a few $5 puts to cover..lol stay warm!

[SmokeSignals]

I'm sleeping with my binoculars on.

[stock1ace1]

Pdufa date to tomorrow 12/23

[stock1ace1]

Fda news tomorrow on drug approval

[Wheat123]

98.6% Institutional ownership.

I'm looking for high institutional ownership companies that are at multi-year lows.

[Big Momma]

Big Momma thinks more to come this week.

[dinogreeves]

"We eagerly anticipate results from additional Phase 3 studies in esophageal, lung, liver, breast, kidney, bladder, stomach, and skin cancers.”

[bigrun]

ok

[dinogreeves]

YW. Just watch it premarket and then decide, if it breaks 23, then I would consider getting in, by the time Robinhood jumps in it should be over 25 and they could push this over 30 tomorrow and as you probably know, Robinhood can only get in after 6:00 AM Cali time. Good luck.

[bigrun]

Thx man

[bigrun]

thx